Finerenone Cuts Heart Failure Events in Preserved Ejection Fraction

FINEARTS-HF extends the nonsteroidal mineralocorticoid receptor antagonist finerenone beyond diabetic kidney disease into heart failure with mildly reduced or preserved ejection fraction, a population renal pharmacists commonly co-manage for potassium and renal risk.

finerenonemineralocorticoid receptor antagonistheart failurepreserved ejection fractionHFpEFhyperkalemiaFINEARTS-HFrandomized controlled trialnephrology Nephrology / Renal Pharmacy

Background Information

Finerenone reduces cardiovascular events in diabetes with kidney disease.

Finerenone, a selective mineralocorticoid receptor antagonist, may provide cardiovascular benefits for patients with type 2 diabetes and chronic kidney disease (CKD). In a study of 7437 patients, finerenone reduced the primary outcome event rate to 12.4% versus 14.2% with placebo, particularly lowering hospitalization for heart failure (hazard ratio 0.71). Finerenone improved cardiovascular outcomes in a diverse CKD population, but higher discontinuation due to hyperkalemia must be managed. Finerenone offers cardiovascular benefits in CKD with type 2 diabetes but requires monitoring for hyperkalemia.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, FIGARO-DKD Investigators

Citation: Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England journal of medicine. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →